FDA panel recommends approval for Vertex cystic fibrosis drug

Correction: An earlier version of this story mischaracterized the FDA's approval process today. The FDA has not yet approved Vertex's drug; an FDA advisory panel has recommended its approval. The Food and Drug Administration's advisory committee has recommended that the FDA approve a new drug from Vertex Pharmaceuticals, which has the potential to help treat an additional 8,500 patients with cystic fibrosis. The drug, Orkambi, has the potential to make the 26-year-old Boston-based drugmaker (Nasdaq:…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news